- Global Pharma News & Resources

Company Directory

PharmiWeb's Pharma Company Directory is a comprehensive and searchable listing of organisations within the Pharma, Biotech & Life Sciences sector. Use it to find partner organisations, suppliers, or even a company to work for!

As an organisation, a basic listing is FREE, and can raise your profile in the industry, making you visible to thousands of monthly site visitors.

To add your organisation to the directory, simply register as a contributor and add your organisation's details. You can also upgrade to a premium listing for only £500/year, this offers even greater scope for added content (more photos, more links, more copy), and even more exposure.

Note that we only accept contributions relating to the Pharma industry and that it will typically take 2 working days to approve (or otherwise) your details. Once approved, you will also be able to contribute press releases and event details to our site.

Create a free account to list your company for free!

ACHIEVA comprises five respected specialist recruitment businesses*1, joining forces to become one stronger and more powerful entity, bolstered by research, development and environmental enterprises that share our core values.
Achilles Therapeutics is a biopharmaceutical company developing personalised T cell therapies targeting neoantigens: protein markers unique to each individual that are present on the surface of a cancer cell and can be detected by the immune system.
As a Swiss pharmaceutical company headquartered in Zurich, we develop, manufacture and internationally market well-proven and innovative pharmaceuticals in novel drug delivery forms. We are a leader in advanced drug delivery technologies with a focus on modified release oral forms, and oral dispersible forms, for which we also hold patents.
We are focused on leveraging core expertise in drug discovery and development and kinase inhibition to develop novel, small molecule therapies to help people impacted by under served immuno-inflammatory conditions. Our team of experienced and accomplished kinome experts use the proprietary KINect® technology platform to generate clinical candidates for difficult to drug kinases with novel approaches.
Acorda’s mission is to develop therapies that restore function and improve the lives of people with neurological disorders.
We are focused on bringing innovation to the treatment of cachexia with a vision to transform care for an under-served and vulnerable patient population, prolong and improve the quality of their lives, restore their dignity and ease the burden for the patient, carer and provider.
We are at a breakthrough moment for Alzheimer’s disease research and drug development. At Acumen, we are leveraging decades of learnings to deliver treatments that can truly impact everyone affected by this devastating disease.
Ad Idem Consulting is a privately-owned, independent recruitment consultancy delivering permanent, interim and contract positions for Finance, Risk & Operations as well as Project Management professionals to businesses of all sizes.
Adagene is a Nasdaq listed, global, clinical-stage immunotherapy company redefining the discovery and design of antibodies to open new horizons in the treatment of cancer. Driven by a powerful platform combining computational biology and artificial intelligence, we create novel antibodies that overcome safety issues and improve efficacy to bring hope to more cancer patients.
Adamas is a fully integrated pharmaceutical company experienced in drug discovery, development, and delivery of treatments for neurological diseases. We are driven by a deep sense of purpose – to make everyday life significantly better for people affected by neurological disorders.
We are an immunotherapy company developing an innovative portfolio of therapeutic antibodies designed to modulate the activity of a patient’s own cytotoxic gamma delta T cells in situ. Our exquisitely targeted approach offers the potential to safely and effectively address the challenges often encountered by current cancer immunotherapies.
Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.
Adaptix is transforming radiology by bringing to market an addressable Flat Panel X-ray Source (FPS) with a multitude of individually addressable emitters with integrated power supply (known as a ‘monoblock’) – essentially we are ‘digitizing’ the source to complete the digitization of the imaging system.
Adare is a global specialized CDMO company with a long history of success from concept through commercialization. We use our unique combination of experience, proprietary capabilities, and resources to create meaningful products for our customers.
Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.
We are a global agency providing comprehensive and innovative medical communication services to the healthcare industry. We build highly collaborative relationships with our clients to achieve great results together. Our relationships are built on knowledge and integrity, which lie at the heart of everything we do.
Adicet is a biotechnology company engaged in the development of first-in-class off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases.
Aditus Medical GmbH is an innovative medical device company in Germany, focused on improving patients’ lives by providing best quality products worldwide. Our products are growth through innovation, continually developing technologies, high-level quality and reliable.
AdoRx Therapeutics is a UK-based drug discovery company and backed by investment from Epidarex Capital and Sixth Element Capital. AdoRx Therapeutics is pursuing the discovery of new therapeutics for cancer-based on modulation of the adenosine pathway. High levels of adenosine in the tumour microenvironment enable cancer to evade the immune system.